Close Menu

NEW YORK — VolitionRx and Gyros Protein Technologies said on Thursday that they have been awarded a combined €946,000 ($1.0 million) in Eurostars grant funding to develop a blood-based lung cancer assay.

Belgium-based VolitionRx received €740,000 in Eurostars funding, whole Uppsala, Sweden-based Gyros, which was recently acquired by Mesa Laboratories, received €206,000.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.